Albireo’s A4250 Receives FDA’s Orphan Drug Designation (ODD) for Biliary Atresia

 Albireo’s A4250 Receives FDA’s Orphan Drug Designation (ODD) for Biliary Atresia

Albireo’s A4250 Receives FDA’s Orphan Drug Designation (ODD) for Biliary Atresia

Shots:

  • Post EMA’s ODD, A4250 has received FDA’s ODD following its P-III study assessing A4250 in patients with Alagille syndrome, biliary atresia and primary biliary cholangitis (PBC)
  • FDA has granted ODD to A4250 for the treatment of Alagille syndrome and primary biliary cholangitis and has also received EMA’s ODD on 18 Dec, 2018 with PRIority MEdicines (PRIME) designation for PFIC
  • A4250 is an ileal bile acid transporter (IBAT) inhibitor targeted for rare pediatric cholestatic liver diseases  evaluated in P-III (NCT03566238) clinical program for patients with PFIC, subtype 1 or 2

Click here to read full press release/ article | Ref:  GlobeNewswire | Image: Sahlgrenska Science Park

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post